Clinical trials: Vision, Ocular
Amblyopia
Assessment of Device for Treatment of Amblyopia
The study will evaluate the effect of Reviview™, a dichoptic video display device for administrating a novel treatment protocol for Amblyopia (lazy eye) in kids.
- Trial name
- NCT02003235
- Testing
- Daily watching videos using Reviview™, a dichoptic video display device, for 60 min
- Where
- Israel
- Volunteers
- 35 people
- Sponsor
- Visior Technologies Ltd.
Ocular Hypertension
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
The purpose of this study is to assess the safety and efficacy of Bimatoprost/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
- Trial name
- NCT00332540
- Testing
- bimatoprost/timolol fixed combination
- Where
- 2 sites in United States, Canada
- Volunteers
- 520 people
- Sponsor
- Allergan
Open-angle Glaucoma
Expanded Access to Bimatoprost (Durysta)
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Durysta (Bimatoprost) prior to approval by the local regulatory agency.
- Trial name
- NCT05338606
- Testing
- Bimatoprost Sustained Release Implant
- Sponsor
- AbbVie
Glaucoma, Ocular Hypertension
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
- Trial name
- NCT00846989
- Testing
- RKI983A, Latanoprost
- Where
- 29 sites in United States
- Volunteers
- 276 people
- Sponsor
- Novartis Pharmaceuticals
Ocular Inflammation and Pain After Cataract Surgery
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
This is a Phase 2a, 2-part study (designated Parts A and B) that will evaluate APP13007 dose strength and dosing frequency in a randomized double-masked fashion for comparison to the respective matching vehicle placebo.
- Trial name
- NCT04089735
- Testing
- APP13007, 0.05%, APP13007, 0.1%
- Where
- 9 sites in United States
- Volunteers
- 165 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Subjects Presenting With Normal or With Ocular Pathology
Clinical Validation of New OCT System
To demonstrate clinical substantial equivalence of DRI OCT-1 as comparable to the commercially available Cirrus
- Trial name
- NCT01809704
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Topcon Medical Systems, Inc.
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2
Diabetes Visual Function Supplement Study
This study will evaluate the effects of a novel multi-component dietary supplement on the visual function and retinal structure of patients with diabetes with both no diabetic retinopathy and mild to moderate diabetic…
- Conditions
- Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
- Trial name
- DiVFuSS (NCT01646047)
- Testing
- multi-component nutritional supplement capsules, multi-component dietary supplement
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- ZeaVision, LLC
Glaucoma, Ocular Hypertension
A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension
The purpose of the study is to examine how preservative free tafluprost ophthalmic solution (0.0015%) is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure.
- Trial name
- NCT02102750
- Testing
- Preservative free tafluprost opthalmic solution
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 17 people
- Sponsor
- Santen Oy
Glaucoma, Open-Angle
Study of an Interposition Supraciliary Implant in Patients With Open Angle Glaucoma
The purpose of this study is to prolong observational follow-up up to 36 months of patients already implanted with a novel interposition supraciliary implant.
- Trial name
- SAFARI FU (NCT05159817)
- Where
- Armenia
- Volunteers
- 19 people
- Sponsor
- Ciliatech
Ocular Inflammation, Infection Associated Blepharitis
Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection
To evaluate the efficacy and safety of fixed combination of azithromycin 1.5% + 0.5% Loteprednol eye drops for the treatment of ocular inflammation and infection associated bacterial blepharitis and / or keratitis and / or…
- Conditions
- Ocular Inflammation, Infection Associated Blepharitis, Keratitis, Conjunctivitis, Bacterial
- Trial name
- NCT01721694
- Testing
- azithromycin 1.5% + Loteprednol 0,5% (separately)
- Where
- Brazil
- Sponsor
- Adapt Produtos Oftalmológicos Ltda.
Hyperopia
Hyperopia Correction Using the NTK Optimal Keratoplasty (Opti-K) System
The purpose of this U.S. Clinical Trial on treatment of sighted eyes is to investigate the safety and effectiveness of optimal keratoplasty (Opti-K™) treatments for hyperopia correction using the NTK Enterprises (NTK) Opti-K…
- Trial name
- NCT01028937
- Testing
- Optimal Keratoplasty
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- NTK Enterprises, Inc.
Glaucoma, Ocular Hypertension
Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
Non-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions.
- Trial name
- XCHANGE (NCT01012245)
- Testing
- no intervention
- Volunteers
- 28,812 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pharyngitis, Tonsillitis
PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
This Post-Authorization Safety Study (PASS) is intended to fulfill a regulatory post-marketing requirement to provide data regarding visual abilities in children taking azithromycin (immediate-release formulation) for acute…
- Trial name
- NCT01919996
- Testing
- Azithromycin
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Pfizer
Cataract, Glaucoma
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension…
- Conditions
- Cataract, Glaucoma, Ocular Hypertension
- Trial name
- NCT07218796
- Testing
- Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- SpyGlass Pharma, Inc.
Advanced/Metastatic NSCLC, Advanced/Metastatic HER2-negative Breast Cancer
A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer
This study will identify risk factors for oral mucositis/stomatitis and ocular surface events (OSE) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) and advanced/metastatic human epidermal growth factor…
- Trial name
- NCT06686602
- Testing
- No drug
- Where
- United States
- Volunteers
- 13,759 people
- Sponsor
- Daiichi Sankyo
Refractive Ametropia
Dispensing Evaluation of Subjective Comfort, Vision, and Handling of a New Lens Compared to a Marketed Lens
To evaluate and compare the performance of a new contact lens to a marketed contact lens.
- Trial name
- NCT01484054
- Testing
- etafilcon A with print and PVP for dark eyes (EAPVPDE), etafilcon A control lens (EADE)
- Where
- 6 sites in United States
- Volunteers
- 103 people
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy
This is a retrospective chart review and will assess changes in IOP after treatment with any fixed combination in patients who previously received monotherapy.
- Trial name
- NCT01637246
- Testing
- Any Fixed Combination Therapy
- Where
- Spain
- Volunteers
- 4,385 people
- Sponsor
- Allergan
Dry Eye Disease
Idroflog® for Treatment of Dry Eye Disease (IDROFLOG)
This study aims at demonstrating the non-inferiority of Idroflog compared to sodium hyaluronate 0.18% for the disease improvement of people with documented history of dry eyes and use of tear substitutes for at least 3 months.
- Trial name
- IDROFLOG (NCT05724056)
- Testing
- Idroflog®, Sodium Hyaluronate 0.18% (Vismed®)
- Where
- 5 sites in France
- Volunteers
- 130 people
- Sponsor
- Alfa Intes Industria Terapeutica Splendore s.r.l.
Myopia
Effects of Projected Peripheral Defocus on Ocular Biometrics
Acucela Inc. intends to develop a medical device to significantly halt or reverse myopic progression, which is a significant public health concern across the world, especially in Asian demographics.
- Trial name
- NCT04388020
- Testing
- Tabletop prototype of eSpecs: Active projection of defocused image in the peripheral visual field, Tabletop prototype of eSpecs: No Active projection of defocused image in the peripheral visual field
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Open-Angle Glaucoma, Ocular Hypertension
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
The purpose of this study was to describe the ocular discomfort immediately upon instillation of Brinzolamide 1%/Brimonidine 0.2% Tartrate Ophthalmic Suspension, Brinzolamide 1% Ophthalmic Suspension, and Brimonidine Tartrate…
- Trial name
- NCT01426867
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2%
- Volunteers
- 103 people
- Sponsor
- Alcon Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.